Swing Trade Ideas

🏃🚀 VTAK high 3.15, up 162%

 ✅ SNTI entry: $0.80
🎯 PT1: $1.20 – $1.85
🎯 PT2: $2.00 – $2.60
🎯 PT3: $2.70 – $3.30
🚫 Stop: Below $0.75 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
Back to near 52wk low from recent high, previously received FDA orphan drug designation for treatment of acute myeloid leukemia, previously received additional $1m from CIRM (California Institute for Regenerative Medicines) to support clinical development, Chardan Capital price target $11, Laidlaw & Co price price $15, company focuses on the development of next-generation cell and gene therapies through tis proprietary Gene Circuit platform, lead candidate, SENT-202, 

 ✅ HCAT potential entry: $1.15-1.20
🎯 PT1: $1.4 – $1.80
🎯 PT2: $1.90 – $2.70
🎯 PT3: $2.80 – $3.50
🚫 Stop: Below $1.0 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup  

   company focuses on healthcare data analytics and technology, providing cloud based data operating system and analytic tools to hospitals and health systems,  Citigroup price target $2.75, Stifel price target $3.75 

 ✅ GNSS entry: $1.70 – $1.75
🎯 PT1: $2.00 – $2.50
🎯 PT2: $2.60 – $3.00
🎯 PT3: $3.10 – $3.90
🚫 Stop: Below $1.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
previously  received $2M order from Singapore Navy for LRAD 950nxtS, previously announced $1M follow-on order from nuclear energy operator, also recently entered strategic partnership with Julie Parker Communications, recently received $9M order from teh US Army for its long range acoustic, also recently secured $1.7M follow-on LRAD order from southeast Asia military as part of multi-year program for long range communication device systems, company provides protective communications solutions, serving the federal, state/local government (SLED), enterprise critical infrastructure , globally in >100 countries and all 50 US states, Roth MKM buy rating 

 ✅ CIGL entry: $1.60
🎯 PT1: $2.00 – $2.50
🎯 PT2: $2.60 – $3.30
🎯 PT3: $3.40 – $3.90
🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to near 52wk low from recent high, recently entered merger agreement with YOOV Group HOlding in a $600 M deal, previously acquired assets of Software Risk to boost facilities management capabilities, recent partnership with Ryde to open new income streams for drivers in Singapore's growing security and facilities sectors , company provides security and safety solutions to commercial, financial, industrial and government clients, 

  ✅ INAB potential entry: $1.40-1.45
🎯 Potential PT1: $1.70 – $2.20, 🎯 PT2: $2.30 – $2.80, 🎯 PT3: $2.90 – $3.50
🚫 Potential Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium / catalyst-driven
previously announced patient 009 in phase 1 trial of INB-200 for newly-diagnosed (glioblastoma multiforme) GBM has reached a significant clinical milestone—achieving a 4-year remission, which far surpasses the progression-free outcomes observed in other clinical trials involving IDH-mutant glioma patients, Soumit Roy buy rating, analyst strong boy rating, HC Wainwright price target $6, company focuses on advancing gamma-delta (γδ) T cell-based therapies targeting cancer and autoimmune diseases

  ✅ MAIA potential entry: $1.40
🎯 Potential PT1: $1.80 – $2.30, 🎯 PT2: $2.40 – $2.80, 🎯 PT3: $3.00 – $3.50
🚫 Potential Stop: Below $1.35 or 2%–5% or daily max risk per trade 

🚦 Risk Level: 🟡 Medium / catalyst-driven

,  Near 52wk low from recent high, recent offering price at $1.50 per share, previously secured European patent for cancer therapy, received FDA fast track designation for Ateganosie for its treatment of non-small cell lung cancer, recently announced agreement with ROCHE for cancer therapies, recently announced positive phase 2 clinical trial, Noble Financial price target $14, company focuses on novel telomere-targeting drug called THIO (ateganosine), aimed at telemerase-positive cancers, especially non-small cell lunch cancer (NSCLC) and pediatric high-trade gliomas, operates multiple clinical-stage programs with a team based in Chicago, 

  ✅ $ACRV potential entry: $1.40
🎯 Potential PT1: $1.60–$2.30, 🎯 PT2: $2.40–$2.80, 🎯 PT3: $2.90–$3.40
🚫 Potential Stop: Below $1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Company focuses on oncology, use a proprietary proteomics/phosphoproteomics platform (AP3) to match tumor's signaling pathways to drug mechanisms, Citizens JMP buy rating, Oppenheimer price target $8, Piper Sandler buy rating 

 ✅ SABS entry: $3.65 – $3.75
🎯 PT1: $4 – $4.50 🎯 PT2: $4.60 – $5.00 🎯 PT3: $5.10 – $5.50
🚫 Stop: Below $3.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 Back to support from recent high, offering at 3.85 per share, , company focuses on immunotherapies, lead platform, DiversitAb, involves producing fully human polyclonal antibodies using genetically engineered cattle that generate human antibodies in response to antigens, goal is to treat unmet medical needs in areas such as infectious disease, immune disorders, Chardan Capital price target $14, Leerink Partners price target $7, Craig-Hallum buy rating, HC Wainwright price target $9, Zacks price target $9 

 ✅ TMDE potential entry: $1.20

🎯 PT1: $1.40 – $1.80 🎯 PT2: $1.90 – $2.40 🎯 PT3: $2.50 – $2.80

🚫 Stop: Below $1.0 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 Back to support from recent high above 4.35, small float, previously announced partnership with Double Corporate for Green Bioenergy Expansion, previously announced expansion into oil waste collection, company specializes in the supply and marketing of marine gas oil and marine fuel oil based in Malaysia and Singapore,, also offers ship management services and vessels chartering. recent IPO 

 ✅ PEPG entry: 4.70
🎯 PT1: 5.10–5.70 🎯 PT2: 5.80–6.50 🎯 PT3: 6.60–6.90
🚫 Stop: Below 4.40 or 2%–5% or daily max risk/trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 ✅ $PRSO potential entry: $1.05–$1.1

🎯 Potential PT1: $1.20 -1.80, 🎯 PT2: $1.90–$2.50, 🎯 PT3: $2.60–$3.50
🚫 Potential Stop: Below $.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat from recent runner,  previously secured $1.1M through inducement offer agreement, ,secured $0.9M order from FWA equipment supplier, partnered with WeLink to expand access to high-speed broadband across dense US metro areas, company focuses on fabless semiconductor/mmWave wireless technology, , Benchmark Co buy rating, price target $3,

 ✅ $STAK entry: $0.90–$0.95
🎯 PT1: $1.20–$1.70 🎯 PT2: $1.80–$2.20 🎯 PT3: $2.30–$2.80
🚫 Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recent IPO, back to near 52wk low from 52wk high above 4.50, company focused on research, development, manufacturing and sale of specialized oil-field production & maintenance equipment 

 ✅  $MRM entry: $1.10– $1.20
🎯 PT1: $1.40 – $1.80 🎯 PT2: $1.90 – $2.40 🎯 PT3: $2.50 – $2.90
🚫 Stop: Below $1.0 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 back support from recent high above 4, recently announced launching new treasury strategy using cryptocurrency, previously announced more than 10,000 people received verified World IDS at $MRM locations, recent partnership announcement with World, co-founded by Sam Altman to double deployment of Orb Human authentication device across Japan, company is a Japan-based holistic healthcare, does have mixed shelf, be mindful on next spik

   ✅PHIO
🎯 Entry: 1.20–1.25
🎯 PT1: 1.40–1.80 🎯 PT2: 1.90–2.50 🎯 PT3: 2.60–3.30
🚫 Stop: Below 1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: Medium | Catalyst-Driven | Technical Setup
back to near key support, recently announced positive clinical data supporting treatment for specific carcinoma,  previously announced partnership with U.S Manufacturer for development of lead compound PH-762, targeting PD-1 gene silencing, for treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma HC Wainwright price target $14, does have mixed shelf, be mindful on next spike 

 ✅ $LRE Entry: $1.25 – $1.35
🎯 PT1: $1.60 – $2.40 🎯 PT2: $2.50 – $2.90 🎯 PT3: $3.00 – $3.60
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
previously proposed dividend of $0.07 per share, expanded operations with launch of "master lease business " and new hotel site in Toyko, announced, company develops and sells luxury residential properties in Japan, also operates hotels in Tokyo and leases apartment building units in Japan and Dallas, TX, 

 ✅ CSAI Entry: $0.55
🎯 PT1: $0.70 – $1.20 🎯 PT2: $1.30 – $1.60 🎯 PT3: $1.70 – $2.50
🚫 Stop: Below $0.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to near 52wk low, small float, recently secured partnership with New England-based property management, previously announced up to $5M share-repurchase program to enhance shareholder value, announced contract to secure luxury high-rise in Houston, announced partnerships with National Property management firm to enhance security with AI Surveillance Solutions, also, announced partnership with Crypto-mining company to cut AI operation costs using renewable energy data center in Montana, won "Project Management Solution of the year", company specializing in cloud-based video surveillance, storage, analytics and monitoring solutions, offering leverage AI and computer vision to enhance security systems, Analyst price target $6, buy rating,  company have until 8/17/2026 to regain Nasdaq compliance by  bringing price above $1 for at least 10 consecutive business days 

 ✅ $MWYN Entry: $0.70 – $0.75
🎯 PT1: $1.00 – $1.70 🎯 PT2: $1.80 – $2.20 🎯 PT3: $2.40 – $3.00
🚫 Stop: Below $0.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
back to near 52wk low, small float, Nevada-based company specializing in sourcing and distributing Asian food, as well as supplying kitchen cabinets and other home improvement products

 ✅ IMUX Entry: $1.10 – $1.15
🎯 PT1: $1.30 – $1.70 🎯 PT2: $1.80 – $2.40 🎯 PT3: $2.50 – $3.40
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

Another rinse and repeat,  company focuses on developing therapies for chronic inflammatory and autoimmune diseases targeting conditions including: multiple sclerosis (MS), ulcerative colitis, Crohn’s disease, and other immune-related disorders., upcoming catalysts: 1) top line data from twin phase 3 expected end of 2026, Chardan Capital buy rating, HC Wainwright price target $5, D. Boral Capital price target $8 

✅ TELO potential entry: $1.20

🎯 Potential PT1: $1.60 – $1.90 🎯 PT2: $2.00 – $2.50 🎯 PT3: $2.60 – $2.80

🚫 Potential Stop: Below $1.0 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
 back to near 52 weak low from recent high,  recently announced positive  preclinical data data for Telonmir-1  in breast cancer, company focuses on reversing biological aging and degenerative diseases, analyst price target $15, earnings 11/12 

✅ $STEC entry: $1.40
🎯 PT1: $1.30 – $1.80 🎯 PT2: $1.90 – $2.50 🎯 PT3: $2.60 – $3.00
🚫 Stop: Below $1.20 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

company focuses on consumer technology, healthcare and enterprise 

 ✅ NVVE potential entry: $0.80
🎯 PT1: $1.10–$1.70 🎯 PT2: $1.80–$2.30 🎯 PT3: $2.40–$3.50
🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently announced battery energy storage system project in Austria, company focuses on EV charging and vehicle-to-gid (V2G), recently secured $5M contract for three battery energy storage systems in Denmark, does have mixed shelf, be mindful on next spike 

 ✅ $AMC Entry: $1.05
🎯 PT1: $1.20 – $2.20
🎯 PT2: $2.30 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $0.70, or 2%–5%, or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast Moving | Technical Setup 

 52wk low,  Macquarie price target $2 

  ✅ FATE potential entry: $1.10–$1.15
🎯 PT1: $1.40–$1.80 🎯 PT2: $1.90–$2.50 🎯 PT3: $2.60–$3.30
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company focuses on developing cellular immunotherapies for cancer and autoimmune diseases, Wedbush buy rating, 

 ✅ BBAI entry: 3.80–3.90
🎯 PT1: 4.20–4.70 🎯 PT2: 4.80–5.50 🎯 PT3: 5.60–5.80
🚫 Stop: Below 3.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
c ompany focuses on AI software on decision intelligence for government and enterprise clients, average analyst price target $5.50 

 ✅ ONCY entry: $0.90 – $0.95
🎯 PT1: $1.20 – $1.80
🎯 PT2: $1.90 – $2.50
🎯 PT3: $2.60 – $3.80
🚫 Stop: Below $0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high, company focuses on the development of first in class intravenously delivered oncolytic virus designed to selectively destroy cancer cells and stimulate the immune system against tumors, previously announced promising Pelareorep data in colorectal cancer, FDA recently agreed on phase 3 trial design for elareorep in pancreatic cancer, planning to launch immunotherapy trial in pancreatic cancer in 2026,  Lake Street buy rating,  RBC Capital buy rating, HC Wainwright raised target price to $10 from $5, director James T. Parsons recently acquired shares  

 ✅ $BKYI entry: $0.60
🎯 PT1: $0.80 – $1.40
🎯 PT2: $1.50 – $1.80
🎯 PT3: $1.90 – $2.50
🚫 Stop: Below $0.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
recently announced collaboration with TD Synnex to provide suite of security solutions to Federal, State, local government agency, partnered for identify-bound biometric with TD SYNNEXT public sector, announced strategic partnership with Visualforma, recently won contract to secure digital identifies for Major Portuguese Municipality,  collaboration news to expand its service  and Boost cybersecurity with Scandinavian IT distributor IT2Trust, recent partnership with Cloud Distribution to expand IAM and biometric security solutions across the middle east CEO and Chairman reported  recent shares purchased, company provides identify & access management and biometric authentication solutions 

 ✅ VTAK potential entry: $1.35 – $1.45
🎯 PT1: $1.60 – $2.30
🎯 PT2: $2.40 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $1.10 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 recently  announced merger agreement to acquire 100% of Fly Flyte,  small float, recently received new VIVO purchase order from hospital in Slovenia, Previously entered distribution agreement with FuMedica,  and announced two patents to be issued by USPTO, previously received Approval for LockeT in the United Kingdom, announced introduction of LockeT product line into Italy, company specializes in medical device based in US, two main products: VIVO system is a non-invasive, ED cardiac mapping system that integrates ECG and imaging data to help localize ventricular arrhythmia origins before procedures, the other is LockeT device, a suture retention tool designed to optimize vascular closure after percutaneous procedures, aiming to speed up hemostasis and patient recovery, 

  ✅ LRHC entry: 0.90
🎯 PT1: 1.20 – 1.80
🎯 PT2: 1.90 – 2.50
🎯 PT3: 2.60 – 3.50
🚫 Stop: Below 0.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to key support near 52wk low from recent high, recently announced to acquire Consensus Core Technologies in all-stock transaction, company is a real estate brokerage and PropTech holding company, recently expanded int AI infrastructure and data centers, recent 1/10 reverse split, ultra small float, recently signed contract to acquire Central Florida Site for AI data center, 

 ✅ JCSE potential entry: $0.90 - $0.95
🎯 Potential PT1: $1.20 - $1.80
🎯 PT2: $1.90 - $2.50
🎯 PT3: $2.60 - $3.60
🚫 Potential Stop: Below $0.80 or 2%-5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high, company designs and sells industrial cleaning systems and filtration equipment used in manufacturing and food service industries, based out in Singapore 

 ✅ ORKT entry: 1.00
🎯 PT1: 1.20 - 1.60
🎯 PT2: 1.70 - 2.30
🎯 PT3: 2.40 - 2.80
🚫 Stop: Below 0.80 or 2%-5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
AI technology/software company, providing IT consultiing, enterprise software solutions, and a no-code application development platform called eMOBIQ 

 ✅ CRON potential entry: $2.40 - $2.50
🎯 Potential PT1: $2.80 - $3.40
🎯 PT2: $3.50 - $4.30
🎯 PT3: $4.40 - $5.50
🚫 Potential Stop: Below $2.20 or 2%-5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 ✅ VHUB entry: $2.05 – $2.10
🎯 PT1: $2.40 – $3.20
🎯 PT2: $3.30 – $4.30
🎯 PT3: $4.40 – $5.50
🚫 Stop: Below $1.80 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to near 52wk low from recent traded on NASDAQ above $40, recent offering at $2.45/share, company focuses on autonomous Smart Store technology, recently announced expanded its integration with Stripe to Power Global network of AI-driven Smart Stores, also recently secured agreements with multiple independent operators to deploy six new VenHub Smart Stores across Las Vegas, 

 ✅ WAI entry: $2.15 – $2.20

🎯 PT1: $2.50 – $2.90
🎯 PT2: $3.10 – $3.60
🎯 PT3: $3.70 – $4.20

🚫 Stop: Below $2.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup

 back to support from recent high, recently secured $4.8M AI robot sales deal, recent reveres split, ultra small float, company offers corporate business training, consulting, advisory and transaction services in China 

 ✅ CMND entry: $1.00 – $1.05
🎯 PT1: $1.20 – $1.80
🎯 PT2: $1.90 – $2.40
🎯 PT3: $2.50 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
back to 52wk low, previopusly reported positive data for CMND - 100 in alcohol use disorder trial, recently enrolled last patient for first cohort of CMND-100 trial for the treatment of AUD (alcohol use disorder) , recently filed and announced publication of US patent application on binge drinking addiction and compulsive behaviors, also established international patent application for therapy targeting obesity and metabolic syndrome in collaboration with SciSparc, also recently secured IRB approval from Hadassah Medical Center for phase 1/2a trial of Novel AUD treatment, company focuses on the development of psychedelic-derived therapeutics for mental health, neurological disorders, lead candidate, CMND-100 for alcohol use disorder (AUD) 

  ✅ YCBD potential entry: $0.65 – $0.70
🎯 PT1: $1.30 – $2.30
🎯 PT2: $2.40 – $3.30
🎯 PT3: $3.40 – $3.80
🚫 Stop: Below $0.50 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 recently announced strategic acquisition of Bluebird Botanicals, previously announced partnership with Bevtalk distribution to expand herbal Oasis THC Selzer distribution across Florida, US based consumer wellness company focuses on CBD and hemp-derived products, have distribution channel via DTC online, $AMZN and retail partners, Maxim group buy rating 

 ✅ NXDR potential entry: $1.50 – $1.60
🎯 PT1: $1.80 – $2.60
🎯 PT2: $2.70 – $3.50
🎯 PT3: $3.60 – $3.80
🚫 Stop: Below $1.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
company provides an online forum, a neighborhood social networking platform that connects neighbors, local businesses, and public agencies including marketplace for goods and services, recently announced partnership with Waze to bring real-time traffic and road alerts to neighbors, Craigh-Hallum buy rating, hedge fund manager Erick Jackson of EMJ Capital long term price target $374, potential the next 100x runner 

 ✅ FLD potential entry: $1.30 – $1.35
🎯 PT1: $1.70 – $2.30
🎯 PT2: $2.40 – $2.80
🎯 PT3: $2.90 – $3.50
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to suport, recently launched No annual fee credit card with up to 4% $BTC.X back monthly , company operates a bitcoin-financial-services platform that enables consumers to earn, save, and use $BTC.X via consumer financial products, recently partnered with Steak n' Shake for BTC.X promotion, CEO previously announced wanting BTC.X gift card to be available in holiday season, Cantor Fitzgerald price target $6.50,  Leerink partners price target $14.5, does have mixed shelf, be mindful on next spike, 

 ✅ NRSN entry: .80
🎯 PT1: 1.30 – 1.90
🎯 PT2: 2.00 – 2.70
🎯 PT3: 2.80 – 3.50
🚫 Stop: Below 0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
back to near 52wk low, recently announced positive trial results for Alzheimer's drug candidate, D. Boral Capital price target $14, Noble financial buy rating, Alliance Global Partners buy rating,  its leading drug candidate, PrimeC, a combination of ciprofloxacin and celecoxib for amyotrophic lateral sclerosis (ALS) has shown positive clinical data in phase 2b, currently being prepared for commercial-scale production, upcoming catalyst: 1) topline data, phase 3, 2nd of half 2026, 2) full lNDS submission later of 2026, 3) phase 2 alzheimer's trial top line expected 2026, company focuses on neurodegenerative diseases, primarily ALS, with additional pipeline programs targeting Alzheimer's and Parkinson's, does have mixed shelf, 

 ✅ SAVA potential entry: $2.10 – $2.20
🎯 Potential PT1: $2.50 – $2.70
🎯 Potential PT2: $2.80 – $2.90
🎯 Potential PT3: $3.00 – $3.70
🚫 Potential Stop: Below $2.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 CEO previously acquired shares, company focuses on developing novel treatments and diagnostics for neurogenerative diseases, especially Alzheimer's disease 

 ✅ BZAI entry: 1.05 – 1.15
🎯 PT1: 1.40 – 1.80
🎯 PT2: 1.90 – 2.50
🎯 PT3: 2.60 – 3.40
🚫 Stop: Below 1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to support, 52wk low from recent high, company develops AI edge computing chips and software platforms used for computer vision, video analytics, industrial automation and smart infrastructure, recently announced partnership with $NOK Nokia solutions and Networks Singapore, B. Riley price target $8, D.A Davidson buy rating, does have mixed shelf, be mindful on next spike, 

 ✅ XAIR potential entry: $0.80
🎯 PT1: $1.20 – $1.70
🎯 PT2: $1.80 – $2.70
🎯 PT3: $2.80 – $3.70
🚫 Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support from recent high above 2, company  is a medical device and biopharm company, focuses on therapies using nitric oxide (NO) technology, its LungFit PH is FDA-approved for pulmonary hypertension in newborns, LungFit PRO/LungFit GO - products for viral lung infections such as pneumonia, bronchiolitis) and at home treatments, NeuroNOS and oncology programs such as solid tumors with ongoing developmentrecently announced acquire 85% of Beyond Air subsidiary NeuroNOS in Autism Therapeutics,  does have mixed shelf, be mindful on next spike, D. Boral price target $11, Rodman & Renshaw buy rating 

 ✅ PRSO potential entry: $0.80
🎯 Potential PT1: $1.20 – $1.70
🎯 PT2: $1.80 – $2.50
🎯 PT3: $2.60 – $3.20
🚫 Potential Stop: Below $0.70 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recently filed application for orphan drug designation for NV-387 to treat measles, recently signed Master services agreements with Only Orphans Cote, company focuses on discovering and developing broad-spectrum antiviral  therapeutics,  former runner,  Alliance Global buy rating 

 ✅ XELB potential entry: $1.40–$1.50
🎯 PT1: $1.70–$2.30
🎯 PT2: $2.40–$2.80
🎯 PT3: $2.90–$3.40
🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup 

 back to support from recent high, company focuses on medica and consumer products, designing, licensing, marketing and selling branded products, band portfolio includes Halston, Judity Ripka, C Wonder, TowerHill by Christie Brinkley, Longaberger and others across apparel, footwear, accessories, home goods, CEO Robert D'Loren and Director Mark DiSanto recently purchased shares, Noble Financial buy rating, does have mixed shelf recently filed, be mindful in next spike 

 ✅ NNVC entry: 1
🎯 PT1: 1.40–1.80
🎯 PT2: 1.90–2.50
🎯 PT3: 2.60–3.30
🚫 Stop: Below 0.85 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup
recently filed application for orphan drug designation for NV-387 to treat measles, recently signed Master services agreements with Only Orphans Cote, company focuses on discovering and developing broad-spectrum antiviral  therapeutics,  former runner,  Alliance Global buy rating 

 ✅ SNGX potential entry: $1.05 – $1.15

🎯 PT1: $1.40 – $1.80
🎯 PT2: $1.90 – $2.60
🎯 PT3: $2.70 – $3.80

🚫 Stop: Below $1.00 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup

 recently received positive orphan drug opinion for SGX945 in Behcet's disease, upcoming catalyst:  ongoing enrollment in phase 3 trial for HyBryte, company specializing in the development and commercialization of therapies for rare and underserved diseases,  Zacks Small-cap price target $35, Alliance Global Partners price target $6, 

✅ FOFO entry: $2.90 – $2.95

🎯 PT1: $3.30 – $3.90
🎯 PT2: $4.00 – $4.60
🎯 PT3: $4.70 – $5.50

🚫 Stop: Below $2.75 or 2%–5% or daily max risk per trade

🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
back to near 52 wk low from recent IPO high above 65, a consulting and asset management firm 

  ✅ HCAT potential entry: $1.70
🎯 PT1: $2.10 – $2.80
🎯 PT2: $2.90 – $3.70
🎯 PT3: $3.80 – $4.50
🚫 Stop: Below $1.65 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🟡 Medium | Catalyst-Driven | Technical Setup 

 back to support near 52wk low, company focuses on healthcare data analytics and technology, providing cloud based data operating system and analytic tools to hospitals and health systems, Citigroup price target $2.75, Stifel price target $3.75 

 ✅ GTBP potential entry: $0.45
🎯 PT1: $0.70 – $1.20
🎯 PT2: $1.30 – $1.80
🎯 PT3: $1.90 – $2.50
🚫 Stop: Below $0.40 or 2%–5% or daily max risk per trade
🚦 Risk Level: 🔴 High | Fast moving | Technical Setup
recently received FDA clearance for IND, previously announced advancing phase 1 trial of GTB-3650 for relapsed blood cancers, update data expecting Q1 2026, other upcoming catalysts: 1)company develops cancer therapies using proprietary TriKE platform, designed to activate natural killer cells to attack cancer cells, ROTH MKM price target $8, does have mixed shelf, be mindful on next spike, have until May 16, 2026 to regain compliance,